Any current/future new fundraising through debt or equity?

The company does not anticipate any major CAPEX going forward; only modest maintenance and debottlenecking CAPEX of around Rs. 5-5.5 crores is expected for the year (Page 8). There is no mention of any planned new equity fundraising; promoter holding is stable at 58% with no plan for further dilution (Page 5). The company is focused on gradually reducing debt by repaying about Rs. 20 crores annually; long-term debts are being repaid quarter-on-quarter (Page 10). Debt reduction to zero is expected over 4-5 years if current repayment rate continues, with potential to pre-close debt earlier du

Any current/future capex/capital investment/strategic investment?

Major CAPEX is largely completed; no major new CAPEX anticipated. Planned maintenance CAPEX and plant debottlenecking expected to be modest, around Rs. 5-5.5 crores for the full year. Unit #5 (Chiplun facility) with 4,500 MT capacity expected to be commissioned in the current financial year and will merge with LASA Laboratories. Unit #6 capacity expanding from 300 MT to 750 MT, with part of it already operational within the current year. Additional capacities totaling approx. 5,350 MT expected to come online this year, increasing total capacity to about 10,750 MT. No significant strategic inve

Future growth expectations in sales/revenue/volumes?

The company targets a conservative sales growth of 12%-15% based on existing capacities and products (Page 8, 18). New developments, including commissioning of Unit #5 and outsourcing initiatives, are expected to add incremental growth beyond the baseline, potentially accelerating growth further (Page 14, 18). Outsourcing business is anticipated to contribute Rs. 20-25 crores, roughly 10% addition to topline, potentially lifting overall growth close to 20%-25% (Page 18). Unit #5 commissioning in the current financial year will increase capacity significantly, expected to boost sales and growth

Future growth expectations in earnings/operating earnings/profits/EPS?

Omkar Speciality Chemicals Limited targets a conservative growth of 12%-15% annually based on existing capacities and products. (Page 6, 8, 13, 18) New developments such as commissioning of Unit #5 and new product approvals are expected to accelerate growth beyond the current 12%-15% guidance. (Pages 13, 18) EBIT margins are maintained around 20%, with occasional quarterly variations depending on product mix; EBITDA margins for Vet API business are around 25%-27%. (Pages 13, 18) Exports are expected to increase from about 10%-12% to 25%-30% of revenues, contributing to growth and better rec

Current/ Expected Orderbook/ Pending Orders?

The company has an order book equivalent to about two months of orders on hand. There is clear visibility of order requirements from major customers for approximately two quarters. Customers typically share their expected quantities for up to December in advance to help in planning raw materials and capacity. Orders are received as per customer requirements, ensuring steady production planning. This applies to existing as well as upcoming capacities such as Unit #5, which will add fungible production capacity usable across products. Overall, the company maintains a healthy order position with

IN US

Sale is live|00:00:00left today

Omkar Speciality Chemicals LtdQ2 FY16Chemicals & Petrochemicals

Omkar Speciality Chemicals Ltd Q2 FY16 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3.41Market Cap: ₹7 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Capex

Yes

1 of 5 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company targets a conservative sales growth of 12%-15% based on existing capacities and products (Page 8, 18).
→New developments, including commissioning of Unit #5 and outsourcing initiatives, are expected to add incremental growth beyond the baseline, potentially accelerating growth further (Page 14, 18).
→Outsourcing business is anticipated to contribute Rs. 20-25 crores, roughly 10% addition to topline, potentially lifting overall growth close to 20%-25% (Page 18).
→Unit #5 commissioning in the current financial year will increase capacity significantly, expected to boost sales and growth (Page 9, 14).
→Exports are expected to improve from Q2 onwards, aiming for 25%-30% of total revenues, contributing to growth (Page 6).
→New product approvals and launches (5-6 approved, 5-6 in pipeline) will also support future revenue increase (Page 6).
→Overall, the company is confident of meeting or exceeding the 12%-15% growth guidance with new capacity and product additions.

Margin guidance

Category 3

→Omkar Speciality Chemicals Limited targets a conservative growth of 12%-15% annually based on existing capacities and products. (Page 6, 8, 13, 18)
→New developments such as commissioning of Unit #5 and new product approvals are expected to accelerate growth beyond the current 12%-15% guidance. (Pages 13, 18)
→EBIT margins are maintained around 20%, with occasional quarterly variations depending on product mix; EBITDA margins for Vet API business are around 25%-27%. (Pages 13, 18)
→Exports are expected to increase from about 10%-12% to 25%-30% of revenues, contributing to growth and better receivables management. (Page 6, 11)
→The company expects improved cash flows and profitability, enabling faster debt repayment possibly ahead of the estimated 4-5 years timeline. (Pages 10, 18)
→EPS and operating profits should grow in line with topline growth and margin maintenance, with further upside from new capacities and products.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company does not anticipate any major CAPEX going forward; only modest maintenance and debottlenecking CAPEX of around Rs. 5-5.5 crores is expected for the year (Page 8).
→There is no mention of any planned new equity fundraising; promoter holding is stable at 58% with no plan for further dilution (Page 5).
→The company is focused on gradually reducing debt by repaying about Rs. 20 crores annually; long-term debts are being repaid quarter-on-quarter (Page 10).
→Debt reduction to zero is expected over 4-5 years if current repayment rate continues, with potential to pre-close debt earlier due to growing revenues (Page 10).
→Some promoter loans are used temporarily for de-pledging shares but these will reduce when shares are de-pledged (Pages 17-19).
→The company is using non-fund based loans and export packing credit to reduce interest costs (Page 6).

Order book

→The company has an order book equivalent to about two months of orders on hand.
→There is clear visibility of order requirements from major customers for approximately two quarters.
→Customers typically share their expected quantities for up to December in advance to help in planning raw materials and capacity.
→Orders are received as per customer requirements, ensuring steady production planning.
→This applies to existing as well as upcoming capacities such as Unit #5, which will add fungible production capacity usable across products.
→Overall, the company maintains a healthy order position with visibility extending at least two quarters ahead.

Capex plans

Yes

→Major CAPEX is largely completed; no major new CAPEX anticipated.
→Planned maintenance CAPEX and plant debottlenecking expected to be modest, around Rs. 5-5.5 crores for the full year.
→Unit #5 (Chiplun facility) with 4,500 MT capacity expected to be commissioned in the current financial year and will merge with LASA Laboratories.
→Unit #6 capacity expanding from 300 MT to 750 MT, with part of it already operational within the current year.
→Additional capacities totaling approx. 5,350 MT expected to come online this year, increasing total capacity to about 10,750 MT.
→No significant strategic investments mentioned beyond capacity expansions and operational improvements.
→Debt of Rs. 35 crores taken for Unit #5 CAPEX, which will be added to LASA's debt upon demerger.
→Outsourcing for specialty chemicals and APIs initiated; forward integration into formulations on LASA side expected in current year.

How does Omkar Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Omkar Speciality Chemicals Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Omkar Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio